LogicBio Therapeutics (OTCMKTS:LOGC) Stock Jumps 0.3% – What’s Next?

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) rose 0.3% on Monday. The stock traded as high as $15.35 and last traded at $15.14. Approximately 154,009 shares were traded during mid-day trading, an increase of 60% from the average daily volume of 95,956 shares. The stock had previously closed at $15.10.

LogicBio Therapeutics Trading Up 0.3%

The company has a quick ratio of 1.24, a current ratio of 1.87 and a debt-to-equity ratio of 0.29. The firm has a market cap of $692.35 million, a price-to-earnings ratio of -20.74 and a beta of 2.04. The business has a 50 day moving average price of $13.70 and a 200-day moving average price of $10.64.

LogicBio Therapeutics (OTCMKTS:LOGC) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The company had revenue of $33.60 million during the quarter, compared to analysts’ expectations of $33.60 million.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing therapies for patients with severe genetic diseases. The company’s research centered on its GeneRide platform, an approach designed to support the targeted insertion of therapeutic genes into the genome and potentially provide durable treatment after a single administration.

LogicBio’s lead investigational program was LB-001, an experimental gene therapy for methylmalonic acidemia, a rare inherited metabolic disorder that primarily affects children.